Proteomics International Laboratories (ASX:PIQ) is a wholly owned subsidiary and trading name of PILL, a medical technology company at the forefront of predictive diagnostics and bioanalytical services. The Company specialises in the area of proteomics - the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.
Proteomics International Laboratories Ltd (ASX:PIQ) announces that its cash reserves have been further strengthened by the receipt of $1.85 million in research and development tax incentive for the 2022-23 financial year.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 September 2023 and subsequent to the period end.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to invite shareholders, investors and interested parties to an online update on the recent announcement regarding the PromarkerD US Reimbursement Price.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce a major milestone in the commercialisation of its predictive test for diabetic kidney disease, PromarkerD, with the US Centers for Medicare & Medicaid Services.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce its latest results for its novel blood test for oesophageal adenocarcinoma will be presented tomorrow at the 19th ISDE World Congress for Esophageal Diseases.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to announce that its subsidiary OxiDx Pty Ltd has been granted a patent in Japan for its platform technology to measure oxidative stress.
It has been a pivotal year for Proteomics International Laboratories Ltd (ASX:PIQ), with the signing of a landmark deal to bring our PromarkerD test for diabetic kidney disease to patients in the United States.
Proteomics International Laboratories Ltd (ASX:PIQ) is pleased to release a copy of the presentation to be provided by Dr Richard Lipscombe to delegates at the 17th Bioshares Biotech Summit on 25 July 2023.
Proteomics International Laboratories Ltd (ASX:PIQ), a medical technology company at the forefront of precision medicine and predictive diagnostics, is pleased to provide the following update on its business activities for the three months to 30 June 2023 and subsequent to the period end.
Issue of Equity Incentives to Employees
Interim Financial Report and Appendix 4D
Issue of Equity Incentives to Employees
Notice of Annual General Meeting/Proxy Form
